Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson's disease.

1-methyl-4-phenyl-1-2- 3-6-tetrahydropyridine (MPTP) Parkinson’s disease alpha synuclein autophagy dopamine transporter dopaminergic neurons lysosome-associated membrane protein 1 (LAMP-1) tauroursodeoxycholic acid tyrosine hydroxylase

Journal

Nutritional neuroscience
ISSN: 1476-8305
Titre abrégé: Nutr Neurosci
Pays: England
ID NLM: 100892202

Informations de publication

Date de publication:
Jul 2022
Historique:
pubmed: 22 12 2020
medline: 22 6 2022
entrez: 21 12 2020
Statut: ppublish

Résumé

Parkinson's disease (PD) is a progressive motor disease of unknown etiology. Although neuroprotective ability of endogenous bile acid, tauroursodeoxycholic acid (TUDCA), shown in various diseases, including an acute model of PD,the potential therapeutic role of TUDCA in progressive models of PD that exhibit all aspects of PD has not been elucidated. In the present study, mice were assigned to one of four treatment groups: (1) Probenecid (PROB); (2) TUDCA, (3) MPTP + PROB (MPTPp); and (3) TUDCA + MPTPp.

Identifiants

pubmed: 33345721
doi: 10.1080/1028415X.2020.1859729
doi:

Substances chimiques

Neuroprotective Agents 0
Taurochenodeoxycholic Acid 516-35-8
ursodoxicoltaurine 60EUX8MN5X
Dopamine VTD58H1Z2X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1374-1391

Auteurs

Elvis Cuevas (E)

Division of Neurotoxicology, National Center for Toxicological Research/FDA, Jefferson, AR, USA.

Susan Burks (S)

Division of Neurotoxicology, National Center for Toxicological Research/FDA, Jefferson, AR, USA.

James Raymick (J)

Division of Neurotoxicology, National Center for Toxicological Research/FDA, Jefferson, AR, USA.

Bonnie Robinson (B)

Division of Neurotoxicology, National Center for Toxicological Research/FDA, Jefferson, AR, USA.

Nancy P Gómez-Crisóstomo (NP)

Universidad Autonoma Juarez de Tabasco, Tabasco, Mexico.

Claudia Escudero-Lourdes (C)

National Center for Toxicological Research, US FDA.

Aida G Guzman Lopez (AGG)

Escuela Nacional Preparatoria-UNAM, Mexico.

Srinivasulu Chigurupati (S)

Office of Regulatory Affairs, Office of Regulatory Science, Food and Drug Administration, Rockville, MD, USA.

Joseph Hanig (J)

Office of Testing & Research, CDER/FDA, White Oak, MD, USA.

Sherry A Ferguson (SA)

Division of Neurotoxicology, National Center for Toxicological Research/FDA, Jefferson, AR, USA.

Sumit Sarkar (S)

Division of Neurotoxicology, National Center for Toxicological Research/FDA, Jefferson, AR, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH